Mechanism of Action
Zeaxanthin and lutein are isomers: same molecular formula, same mass, a single double bond sitting elsewhere on a terminal ring. That structural detail is enough to change where each one ends up in the retina.
Carried by lipoproteins, the fat shuttles of the blood, zeaxanthin reaches the macula, where a binding protein holds it selectively. It concentrates at the centre of the fovea, where the cones, the cells of colour and detail vision, are packed most tightly. Lutein predominates at the periphery. This sorting explains how a pigment present only in traces on the plate reaches a concentration in the macula far above that of plasma.
Its long chain of alternating double bonds absorbs light between 400 and 500 nm, the most energetic band of the visible spectrum. This is an optical property of the molecule, measured in the laboratory. The same chain reacts in the test tube with reactive oxygen species, those unstable molecules produced by metabolism.
In humans, what is measured is the deposit: macular pigment optical density, read without any sampling. It rises slowly, over several months, and depends on the fat in the meal taken alongside.
Key Benefits
- Moderate
A denser macular pigment: in adults with healthy eyes, a synthesis of forty-six studies (3,189 participants, mean age 43) measures optical density rising by 0.04 units between 5 and 20 mg per day of lutein and zeaxanthin, and by 0.11 units above 20 mg, over three to twelve months.
- Moderate
Vision returning faster after glare: in 115 young healthy adults, one year on 10 mg of lutein and 2 mg of zeaxanthin daily shortened recovery time versus placebo. Two meta-analyses confirm it, one of which puts the gain at 2.35 seconds.
- Moderate
Better discrimination of colour contrast: a placebo-controlled trial in 115 young healthy adults, on 10 mg of lutein and 2 mg of zeaxanthin daily for one year, measures improved chromatic contrast.
Dosage & Forms
Two isomers circulate under the name zeaxanthin. The dietary one, described as trans, comes from corn, yellow peppers and egg yolk. The second, meso-zeaxanthin, is almost absent from the plate and is obtained by transformation of lutein.
Trials that administered zeaxanthin on its own worked between 8 and 20 mg per day, over six to twelve months. Those on the pair give 2 mg alongside 10 mg of lutein, a ratio close to that of the diet, estimated at around five to one.
Doses in the syntheses are read on the lutein plus zeaxanthin total, since the two arrive together. Below 5 mg per day, a synthesis of forty-six studies records no clear change in macular pigment. Its 5 to 20 mg stratum measures a gain of 0.04 optical density units, and its above 20 mg stratum a gain of 0.11 units. Observed durations run from three to twelve months, the time the deposit needs to reach its plateau.
On safety, the acceptable daily intake set by the European authority corresponds to about 53 mg per day in a 70 kg adult.
In the Singular Formula
Inclusion rationale
Carotenoid of the xanthophyll family, an isomer of lutein from which it differs only by the position of one double bond. That structural nuance decides its destination: zeaxanthin deposits at the centre of the fovea, the area of the retina where cones are densest, while lutein occupies the periphery of the macula. Together the two form the macular pigment, and the two travel together: the same raw material supplies them in a ratio close to that of our diet. It is also the ratio administered in the reference trials, which makes their results directly readable. The density of this pigment is measured in humans without any sampling, and it rises with intake: this is the quantity on which most trials rest. The body does not synthesise zeaxanthin. Intakes recorded in European adults remain well below the doses used in trials.
Selected form
XanMax® 2505 is the carrier raw material, an extract of Tagetes erecta flowers obtained with hexane and ethanol at a 400:1 extraction ratio. Its xanthophyll crystals are formulated with dextrin, gum acacia and tocopherols, which slow oxidation of the pigment. A single weighing supplies both lutein and zeaxanthin, in the ratio set by the standardisation of the material: at least 25% lutein and 5% zeaxanthin.
Formula dosage
0 to 4 mg.
Dose expressed as active substance, excluding excipients and carriers of the raw material.
Synergies in the formula
Safety & Precautions
Zeaxanthin has a long record of use. The AREDS2 trial followed more than four thousand adults for five years on 10 mg of lutein and 2 mg of zeaxanthin, with no notable adverse effect attributed to that combination.
Safety assessments leave wide margins. The acceptable daily intake set by the European authority corresponds to about 53 mg per day in a 70 kg adult. An international committee has separately set a value shared by lutein and zeaxanthin, more permissive still.
Prolonged carotenoid supplementation can give the skin a yellowish tint known as carotenodermia. The phenomenon is benign and fades on stopping.
Zeaxanthin is not converted to vitamin A by the body, which rules out the accumulation risk specific to retinol. It belongs to a different family from beta-carotene, which the large ocular trials replaced with it, and the European authority considers it unlikely to carry the same risk profile in heavy smokers. Medicines that reduce fat absorption may also reduce carotenoid absorption.
During pregnancy or breastfeeding, the formula limits the combination to 10 mg of lutein and approximately 2 mg of zeaxanthin per day.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Wilson LM et al. | 2021 | Meta-analysis | Advances in Nutrition | View on PubMed |
The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis Forty-six studies, 3,189 adults with healthy eyes, results stratified by dose. Below 5 mg per day, no clear change. From 5 to 20 mg, macular pigment density gains 0.04 units; above 20 mg, 0.11 units. Strength of evidence rated moderate by the authors. | ||||
| Hammond BR et al. | 2014 | Randomised Controlled Trial | Investigative Ophthalmology & Visual Science | View on PubMed |
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast One hundred and fifteen young healthy adults, 10 mg of lutein and 2 mg of zeaxanthin daily for one year. Chromatic contrast and photostress recovery time improved versus placebo, and macular pigment density rose at every eccentricity measured. Glare disability, however, did not change significantly in the supplemented group. | ||||
| Hu W et al. | 2024 | Meta-analysis | Advances in Nutrition | View on PubMed |
Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Thirty-eight controlled trials compared in a network. Every supplemented group raised macular pigment density and contrast at low spatial frequency, with no gain at normal or high frequencies. The lutein plus zeaxanthin combination is the only one to significantly shorten photostress recovery time. The authors rate the quality of evidence as low. | ||||
| Hu W et al. | 2023 | Meta-analysis | Nutrition Reviews | View on PubMed |
Effect of xanthophyll-rich food and supplement intake on visual outcomes in healthy adults and those with eye disease: a systematic review, meta-analysis, and meta-regression of randomized controlled trials Forty-three articles retained, twenty-five pooled. Xanthophyll intake raises macular pigment density by both measurement methods and shortens photostress recovery time by 2.35 seconds. The visual acuity gain appears only in people with an eye condition, not in adults with healthy sight. | ||||
| Schalch W et al. | 2007 | Randomised Controlled Trial | Archives of Biochemistry and Biophysics | View on PubMed |
Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study The only programme to have given zeaxanthin alone against lutein alone and against their combination, at 10 or 20 mg per day for six to twelve months. Plasma concentrations rose up to twenty-seven-fold. Zeaxanthin raised pigment density by 14% after correction, but it deposits over a wider retinal area than lutein, which complicated the measurement. | ||||
| Richer SP et al. | 2011 | Randomised Controlled Trial | Optometry | View on PubMed |
Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) Sixty adults averaging 75 years, with mild-to-moderate atrophic macular involvement, followed for one year across three arms: 8 mg of zeaxanthin, 8 mg of zeaxanthin with 9 mg of lutein, or 9 mg of lutein alone. Pigment density rose in all three groups, with no difference between them. The arm receiving both carotenoids at similar doses, a ratio far from that of the diet, is the one where pigment rose least: the authors read this as competition for absorption. | ||||
| Obana A et al. | 2015 | Randomised Controlled Trial | PLoS One | View on PubMed |
Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements Thirty-six healthy volunteers, randomised double-masked between two marigold extracts, one of them XanMax®, the material selected by Singular, which supplied 1.29 mg of zeaxanthin per day. After six months, mean macular pigment density did not increase significantly in either group, and contrast sensitivity stayed flat. The trial compares two products with no placebo arm, on eighteen subjects per group. | ||||
| Age-Related Eye Disease Study 2 Research Group | 2013 | Randomised Controlled Trial | JAMA | View on PubMed |
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial Four thousand two hundred and three adults aged 50 to 85, five years of follow-up, 10 mg of lutein and 2 mg of zeaxanthin added to the formulation all participants received. The primary analysis did not reach significance on progression to the advanced form (HR 0.90; P = 0.12). The contribution of the trial lies elsewhere: it allowed beta-carotene to be replaced, its follow-up having shown an excess lung risk in former smokers. | ||||